<!DOCTYPE html>
<html>
<head>
<title>EP Trials Review 2020: EAST-AFNET4</title>
<!-- Global site tag (gtag.js) - Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=UA-119340815-7"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'UA-119340815-7');
</script>

</head>

<meta name="viewport" content="width=device-width, initial-scale=1">
<link rel="icon" href="box transparent.png" type="image/png" sizes="60x60">
<link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
<link href="https://fonts.googleapis.com/css2?family=Eczar&family=Rubik&display=swap" rel="stylesheet">
<script src="https://kit.fontawesome.com/2c3e1e841c.js" crossorigin="anonymous"></script>

<!--auto-ad-->
<script data-ad-client="ca-pub-1548733331544768" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>

<!-- Global site tag (gtag.js) - Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=UA-119340815-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'UA-119340815-1');
</script>

<style>
/*fonts*/
.sans {font-family: 'Rubik', sans-serif;}
.serif {font-family: 'Eczar', serif;}

.headLine {
    font-family: 'Eczar', serif;font-size: 2.8vmax;line-height: 120%;
}
.pGraph {
    font-family: 'Rubik', sans-serif;font-size: 1.7vmax;line-height: 120%; 
    color: #555555;text-indent: 4vmax;padding-top: 2vmax;text-align: justify;
}
.figure {padding:1.5vmax;width: 100%;border: #ddd solid 0.1vmin;margin-top: 2vmax;}
.caption {font-family: 'Eczar', serif;font-size: 1.5vmax;line-height: 120%;color: #a8a8a8;padding-bottom: 2vmax;}
.ref {font-size: 0.9vmax;color: #777777;font-family: 'Rubik', sans-serif;
line-height: 120%;margin-top: 0.5vh}

</style>

<body>
<!--main title-->
 
<div class="w3-center" style="line-height: 200%;width: 100%;padding: 3vmax 0;">
    <div>
        <a href="https://heartrhythmbox.com" target="_blank">
            <img src="box transparent.png" style="width: 4vmax;padding-bottom: 1.5vmax;"></a>
    </div>
    <div class="serif" style="font-size: 5vmax;padding: 1vmax;">
        EP Trials Review
    </div>
    <div class="sans" style="font-size: 1.5vmax;color: #555555;background-color: #eeeeee;">
        EAST-AFNET4
    </div>
</div> 

<!--content-->
<div style="width:auto;max-width: 800px;margin-left: auto;margin-right: auto;padding:1vmax">
        <div class="headLine">
            Early Rhythm-Control Therapy in Patients with Atrial Fibrillation
        </div>
        <div class="ref">
            Ref:
            <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2019422" target="_blank">
                EAST-AFNET4. NEJM 2020.
            </a></div>
        <div class="pGraph">
            In this international, investigator-initiated, parallel-group, open, 
            blinded-outcome-assessment trial, the investigators randomly assigned patients 
            who had early atrial fibrillation (diagnosed â‰¤1 year before enrollment) 
            and cardiovascular conditions to receive either early rhythm control or usual care.
        </div>
        <div class="pGraph">
            N = 2789, mean age 70, 46% female, f/u 5.1yrs.
            The first primary outcome was a composite of death from cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome.
        </div>
        <img src="media/EAST AFNET/rhythmControl.png" class="figure">
        <div class="caption">
            Type of rhythm control. 
            <span style="font-size: 1vmax;">
            Prop = Propafenone, Flec = Flecainide, Amio = Amiodarone, Dron = Dronedarone, Abl = Ablation</span>
        </div>
        <div style="border-bottom:double 0.3vmax #797979;height: 2vh;padding: 2vmax;">
        </div> 
        <img src="media/EAST AFNET/KM.png" class="figure">
        <div class="caption">
            Cumulative Incidence for the First Primary Outcome. 
            HR (early rhythm control vs. usual care), 0.79; 96%CI, 0.66 to 0.94; P=0.005.
        </div>
        <div class="pGraph">
            The trial was stopped for efficacy at the third interim analysis after 
            a median follow-up of 5.1 years per patient. 
            A first-primary-outcome event occurred in 249 patients assigned to receive 
            early rhythm control (3.9 per 100 person-years) and in 316 patients assigned 
            to receive usual care (5.0 per 100 person-years).
        </div>
        <div style="border-bottom:double 0.3vmax #797979;height: 2vh;padding: 2vmax;">
        </div> 
        <div class="pGraph">
            In AFFIRM, rhythm control was not associated with better CV outcomes than rate control.
            Rhythm control was on the other hand associated with higher non-CV death than rate control,
        </div>
        <div class="ref">
            Ref:
            <a href="https://doi.org/10.1161/01.CIR.0000118472.77237.FA" target="_blank">
            Specific Mortality in AFFIRM. Circulation 2004.
            </a>
        </div>
        <img src="media/EAST AFNET/AFFIRM nonCV.png" class="figure">
        <div class="caption">
            Cumulative noncardiovascular mortality in the rhythm-control and rate-control groups in AFFIRM.
        </div>
        <div class="pGraph">
            The type of rhythm control treatment in AFFIRM vs. EAST-AFNET4 is shown here. 
        </div>
        <img src="media/EAST AFNET/AFFIRMcomparisons.png" class="figure">
        <div class="caption">
            Type of rhythm control EAST-AFNET4 vs. AFFIRM. 
            <span style="font-size: 1vmax;">
            Prop = Propafenone, Flec = Flecainide, Amio = Amiodarone, Dron = Dronedarone, Abl = Ablation, 
            Quin = Quinidine, Sota = Sotalol, Proc = Procainamide.    
        </span>
        </div>
        <div style="border-bottom:double 0.3vmax #797979;height: 2vh;padding: 2vmax;">
        </div>
        <div class="pGraph">
            The CV events in both groups were relatively low. In both group, the incidence of stroke was less than 1 in 100 person-year
            and the all-cause mortality was less than 1.5 per 100 person-year.
            The adverse events were also low, though slightly higher in rhythm control group.
        </div>
        <img src="media/EAST AFNET/events.jpeg" class="figure">
   
    <!--home/top-->
    <div class="sans" style="padding-top: 3vmax;">
    <a href="index.html" target="_blank">
        <i class="fas fa-home" 
        style="font-size: 2vmax;color:#a8a8a8;"></i></a>
    &nbsp;&nbsp;
    <a href="#top"><i class="fas fa-arrow-circle-up" style="font-size: 2vmax;color: #a8a8a8;"></i>
    </a>
    </div>

</div>



<!--end page-->
<div class="w3-container sans w3-center" 
style="margin-top:10vh;background:#f1f1f1;font-size: 1vmax;padding: 2vmax;color:#797979">
    <img src="box transparent.png" style="width: 2vmax;">
    <br>
    HeartRhythmBox, an education page of heart rhythm topics.<br>
    visit us at <a href="https://heartrhythmbox.com" target="_blank">
    www.heartrhythmbox.com</a><br>
    or <a href="https://www.facebook.com/HeartRhythmBox/" target="_blank">https://www.facebook.com/HeartRhythmBox/</a>
</div>


</body>

</html>